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Letters e65sequelae.1-3 DM has been implicated in only 9 case
reports, including our own.4 Five of the 8 prior cases
were patients with underlying rheumatoid arthritis;
one had Crohn disease, one had underlying
juvenile idiopathic arthritis, and one had seronega-
tive inflammatory arthritis.4 Four of the previous 8
cases were induced by adalimumab, 3 were induced
by etanercept, and 1 was induced by both
adalimumab and etanercept.4 In many of the
previous reports, direct causality was difficult to
establish due to the length of time between therapy
initiation and symptom development.4 In our case,
the DM symptoms began after 1 month of treatment,
making causality more likely.
a-TNF agents continue to be a safe and effective
treatment for various dermatologic and rheumato-
logic conditions. Due to the increasing popularity
of these agents, practitioners should be cognizant
of their potential to paradoxically induce autoim-
mune disease. The spectrum of presentations can
be widely varied and can exhibit symptomatic
overlap with other connective tissue disease.
Therefore, it is imperative to maintain a high
degree of clinical suspicion when prescribing these
medicines.
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Drug hypersensitivity syndrome in a patient
receiving vismodegib
To the Editor: Vismodegib (Erivedge) is a hedgehog
signaling pathway inhibitor that is FDA-approved for
the treatment of advanced basal cell carcinoma
(BCC).1 Common adverse effects include nausea,
vomiting, dysgeusia, decreased appetite, and weight
loss.1 Here we present a patient treated with vismo-
degib who developed drug hypersensitivity syn-
drome (DHS).
A 77-year-old woman presented with numerous
primary and recurrent BCCs on her face, trunk, and
extremities. Her past medical history was significant
for psoriasis that was treated with whole body
radiation decades earlier and currently controlled
with ustekinumab 45 mg subcutaneously every 3
months for the past 2 years. After much consider-
ation and numerous prior surgeries, she was started
on oral vismodegib 150 mg daily to treat more than
20 primary and recurrent BCCs (off-label indication).
Three weeks into treatment, nausea, vomiting, dys-
geusia, decreased appetite, and weight loss abruptly
developed; all are common adverse effects of
vismodegib. Additionally, she had chills, myalgias,
and extreme fatigue. The medication was discon-
tinued due to intolerability. Because there were rare
reports of treatment-emergent electrolyte distur-
bances in clinical trials of vismodegib,2 empirical
laboratory specimens drawn 2 days after discontinu-
ing the medication were remarkable for AST 143 U/L
(normal 15 to 41), ALT 200 U/L (normal 7 to 35),
alkaline phosphatase 345 U/L (normal 32 to 120),
and total bilirubin 4.4 mg/dL (normal 0.3 to 1.2).
White blood cell count was normal at 7.5 but with
eosinophilia of 17.9% (absolute eosinophils 1300/
L). Basic metabolic profile was normal. Due to the
mixed pattern of liver abnormalities, abdominal
ultrasoundwas performed andwas noncontributory.
Liver panel was improved 10 days after discontinu-
ing vismodegib and was completely normal after 1
month. By this time, her only complaint was a
residual ‘‘fuzzy tongue’’ sensation that resolved
over the next 3 months. A thyroid stimulating hor-
mone and free T4 level were normal 4 months later.3
Repeat laboratory evaluation after her next usteki-
numab injection, including white blood cell count of
7.4 with 0.9% eosinophils, was also normal.
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peripheral eosinophilia and systemic symptoms
reported 3 weeks after starting vismodegib and
complete resolution following discontinuation, we
believe this patient had a DHS secondary to vismo-
degib.4 It is unclear what role her concurrent use of
ustekinumab played, but she has not had recurrence
of her symptoms or laboratory abnormalities
following continued use of this medication alone.
In conclusion, DHS should be included as a
potential adverse effect of vismodegib. Practitioners
should be made aware of this possibility so that
patients reporting severe symptoms are given appro-
priate laboratory and clinical evaluations for prompt
diagnosis and management.5
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